BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

SAN CARLOS, Calif.--(BUSINESS WIRE)--Aug 29, 2025-

BeOne reports topline MCL trial outcomes of BCL2 inhibitor

BeOne Medicines has shared encouraging topline outcomes from its Phase I/II trial, BGB-11417-201, evaluating sonrotoclax.The post BeOne reports topline MCL trial outcomes of BCL2 inhibitor appeared first on Clinical Trials Arena.

Promising BCL2 Inhibitor Shows Efficacy in Relapsed Mantle Cell Lymphoma

Sonrotoclax shows promise as a new treatment for relapsed/refractory mantle cell lymphoma, achieving significant response rates in heavily pretreated patients.

BeOne plots accelerated approval for rare lymphoma drug after toplining Phase 1/2 data

BeOne Medicines said its candidate for a rare but aggressive form of B cell lymphoma has passed an early-stage test. Its BCL2 inhibitor, known as sonrotoclax, met the primary endpoint of overall response rate in ...